Candesartan for hypertension.
D000284:Administration, Oral; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D013777:Tetrazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan